1. 2020
  2. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

    Keymeulen, B., van Maurik, A., Inman, D., Oliveira, J., McLaughlin, R., Gittelman, R. M., Roep, B. O., Gillard, P., Hilbrands, R., Gorus, F., Mathieu, C., Van de Velde, U., Wisniacki, N. & Napolitano, A., 4 Nov 2020, In : Diabetologia.

    Research output: Contribution to journalArticle

  3. Use of culture to reach metabolically adequate beta cell dose by combining donor islet cell isolates for transplantation in type 1 diabetes patients

    Lee, D., Gillard, P., Hilbrands, R., Ling, Z., Van de Velde, U., Jacobs-Tulleneers-Thevissen, D., Maleux, G., Lapauw, B., Crenier, L., De Block, C., Mathieu, C., Pipeleers, D. & Keymeulen, B., 2020, In : Transplantation. 104, 10, p. e295-e302 8 p.

    Research output: Contribution to journalArticle

  4. 2019
  5. Bètaceltransplantatie: indicaties en doelstellingen anno 2019

    Hilbrands, R., Van Hulle, F. O. & De Paep, D. L., Dec 2019, In : Bloedvaten, Hart en Longen. 24, 10, p. 38-41 4 p.

    Research output: Contribution to journalArticle

  6. A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development

    De Franco, E., Watson, R. A., Weninger, W. J., Wong, C. C., Flanagan, S. E., Caswell, R., Green, A., Tudor, C., Lelliott, C. J., Geyer, S. H., Maurer-Gesek, B., Reissig, L. F., Lango Allen, H., Caliebe, A., Siebert, R., Holterhus, P. M., Deeb, A., Prin, F., Hilbrands, R., Heimberg, H. & 3 others, Ellard, S., Hattersley, A. T. & Barroso, I., 2 May 2019, In : American Journal of Human Genetics. 104, 5, p. 985-989 5 p.

    Research output: Contribution to journalArticle

  7. Acid-base and electrolyte disturbances in patients with diabetes mellitus

    Pipeleers, L., Wissing, K. M. & Hilbrands, R., 2 Jan 2019, In : Acta Clinica Belgica. 74, 1, p. 28-33 6 p.

    Research output: Contribution to journalArticle

  8. Identification and characterisation of the dose response of otelixizumab in new onset type 1 diabetes patients

    Napolitano, A., van Maurik, A., Inman, D., Wisniacki, N., Gillard, P., Hilbrands, R., Gorus, F., Mathieu, C., Van De Velde, U. & Keymeulen, B., 2019, In : Diabetologia. 62, suppl 1, p. S224-S224 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

  9. 2018
  10. 2017
Previous 1 2 3 4 Next

ID: 29272